Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Accounts Receivable : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Entasis Therapeutics Holdings's accounts receivables for the quarter that ended in Mar. 2022 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Entasis Therapeutics Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $0.13.

Entasis Therapeutics Holdings Accounts Receivable Historical Data

The historical data trend for Entasis Therapeutics Holdings's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entasis Therapeutics Holdings Accounts Receivable Chart

Entasis Therapeutics Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Receivable

Get a 7-Day Free Trial

Entasis Therapeutics Holdings Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Entasis Therapeutics Holdings Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Entasis Therapeutics Holdings Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Entasis Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Entasis Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:

Entasis Therapeutics Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(33.547	+	0.75 * 0	+	0.5 * 0	-	27.443
-	0	-	0)	/	47.8518
=	0.13

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Entasis Therapeutics Holdings Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Gatehouse Drive, Waltham, MA, USA, 02451

Website

https://www.entasistx.com

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Executives

Theravance Inc	10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner	officer: VP, Principal Fin & Acct Off	35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac	officer: Chief Medical Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch	officer: Chief Fin. and Bus. Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller	officer: Chief Development Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros	director, officer: President and CEO	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi	officer: Chief Scientific Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim	officer: See Remarks	35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley	officer: General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola	officer: Chief Commercial Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble	officer: Chief Commercial Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451